Laís Cristhine Santos Souza

Laís Cristhine Santos Souza

Auto-generated profile, based on publicly available information

Laís Cristhine Santos Souza

Transplantation, State University of Ceará, Fortaleza, Brazil

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2023 in Clinics
Verified
Journal Article
Open access
ABAntonio Braga
Antonio Braga
EBElaine Balthar
Elaine Balthar
LSLaís Cristhine Santos Souza
Laís Cristhine Santos Souza
MSMichelle Samora
Michelle Samora
MRMatheus Machado Rech
Matheus Machado Rech
RBRoss Berkowitz
Ross Berkowitz
To evaluate the efficacy of immunotherapy for GTN treatment after methotrexate-resistance or in cases of multiresistant disease, through a systematic review, as well as to present the first 4 Brazilian cases of immunotherapy for GTN treatment. Three independent researchers searched five electronic databases (EMBASE, LILACS, Medline, CENTRAL and Web of Science), for relevant articles up to February/2023 (PROSPERO CRD42023401453). The quality assessment was performed using the Newcastle Ottawa scale for case series and case reports. The primary outcome of this study was the occurrence of complete remission. The presentation of the case reports was approved by the Institutional Review Board. Of the 4 cases presented, the first was a low-risk GTN with methotrexate resistance unsuccessfully treated with avelumab, which achieved remission with sequential multiagent chemotherapy. The remaining 3 cases were high-risk multiagent-resistant GTN that were successfully treated with pembrolizumab, among which there were two subsequent gestations, one of them with normal pregnancy and healthy conceptus. Regarding the systematic review, 12 studies were included, only one of them on avelumab, showing a 46.7% complete remission rate. The remaining 11 studies were on pembrolizumab, showing an 86.7% complete remission rate, regardless of tumor histology. Both immunotherapies showed good tolerability, with two healthy pregnancies being recorded: one after avelumb and another after pembrolizumab. Immunotherapy showed effectiveness for GTN treatment and may be especially useful in cases of high-risk disease, where pembrolizumab achieves a high therapeutic response, regardless of the histological type, and despite prior chemoresistance to multiple lines of treatment.

1 April 2018 in Transplantation Proceedings
Verified
Journal Article
Open access
VCV. Cestari
V. Cestari
VPV.L. Pessoa
V.L. Pessoa
JNJ.D. de Souza Neto
J.D. de Souza Neto
TMTHEREZA MARIA MAGALHAES MOREIRA
THEREZA MARIA MAGALHAES MOREIRA
RFR. Florêncio
R. Florêncio
MSM.G. Sobral
M.G. Sobral
To evaluate the clinical evolution of patients with implantation of ventricular assist device (VAD) and identify the intervening factors for death. This analytical, retrospective study was carried out in a public reference hospital in cardiopulmonary diseases located in northeastern Brazil. The study population encompassed the medical records of 16 patients who underwent VAD implantation. Data collection took place from January to August 2016, through the consultation of medical records. Descriptive analysis, odds ratio, and the Fisher's Exact, Wilcoxon, Friedman and t-tests were used to analyze the data. All patients experienced complications during the use of the device, with bleeding being the main cause (11 [68.8%]). There was a significant decrease in noradrenaline (P = .025), milrinone (Primacor; P = .007), and dobutamine (P = .046) flow rates with the clinical evolution of patients. Regarding hematologic parameters, the use of VAD promoted a significant improvement in hemoglobin (P < .001), hematocrit (P = .003), activated partial thromboplastin time (P = .013), and fibrinogen (P = .049) values at the 3 time points analyzed. Regarding the clinical outcome of the patients, the majority (10 [62.5%]) underwent cardiac transplantation. This study allowed for better knowledge of the clinical evolution of patients with VAD implantation, highlighting the benefits of this type of device as a bridge for heart transplantation.

17 July 2026 in Revista Brasileira de Ginecologia e Obstetrícia
Verified
Journal Article
Closed access
LSLaís Cristhine Santos Souza
Laís Cristhine Santos Souza
MAMichelle Samora de Almeida
Michelle Samora de Almeida
ABAntonio Braga
Antonio Braga
JMJosé Mauro Madi
José Mauro Madi
Edward Araujo JúniorEdward Araujo Júnior
Edward Araujo Júnior
SSSue Yazaki Sun
Sue Yazaki Sun